\n
\nDescription:
\n
\nMoxifloxacin is a synthetic broad spectrum, fluoroquinolone derivative antibacterial agent. Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative microorganisms. The bactericidal action of Moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.
\n
\nComposition:?Each film-coated tablet contains Moxifloxacin Hydrochloride BP equivalent to Moxifloxacin 400 mg
\n
\nIndication:?Cubimox is indicated for the treatment of adults (>18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below-
\n
\n
Acute Bacterial Sinusitis
\n
Acute Bacterial Exacerbation of Chronic Bronchitis
\n
Community Acquired Pneumonia
\n
Uncomplicated Skin and Skin Structure Infections
\n
Complicated Skin and Skin Structure Infections
\n
Complicated Intra-Abdominal Infections
\n
Acute Pelvic Inflammatory Disease
\n
\nDosage & Administration:?The dose of Cubimox is 400 mg once every 24 hours (for adults)
\n
\nOr, as advised by the physician.
\n
\n